LinkedIn·Tuesday, 4 August 2026·22d ago

Your electronic product information (ePI) implementation could go live without making the information meaningfully easier for an HCP to…

Vivanti

983 followers

Your electronic product information (ePI) implementation could go live without making the information meaningfully easier for an HCP to use. 💻 Recent European Medicines Agency industry updates covered the ePI roadmap and go-live planning for centrally authorised vaccines. The planned roll-out is currently targeted for Q4 2026. This work creates an important digital foundation. It does not, by itself, create better HCP communication. An HCP rarely approaches product information with time to read it from beginning to end. They arrive with a specific clinical question: Where is the relevant dosing adjustment? Which contraindication applies? What does the latest safety information mean for this patient? How does the evidence support the treatment decision? A structured regulatory source can answer those questions and still make the answers difficult to reach. This is the distinction pharma teams need to address. ePI provides the controlled source of approved product information. Pharma can then create clearer HCP-facing content experiences anchored to that source, subject to the relevant medical, regulatory and promotional controls. 🔎 That experience might include a clearer route into the relevant section, an interactive explanation of complex evidence, a visual mechanism of action, a mobile-first product-information hub or educational content that remains anchored to the approved source. The ePI opportunity does not end when the information is published. That is where the HCP experience begins. Reflection: Is your ePI implementation designed only to make product information available, or to make approved information genuinely easier for HCPs to use? #ePI #HCPEngagement #MedicalContent #RegulatoryAffairs #DigitalPharma

💬 1↻ 1

View on LinkedIn